Eli Lilly (NYSE:LLY) is the most valuable healthcare company, with Johnson & Johnson (NYSE:JNJ) and AbbVie (NYSE:ABBV) rounding out the top three. Pharmaceutical companies dominate this market sector, comprising more than half of the largest healthcare companies by market cap.
The 10 largest
Largest companies by market cap in the healthcare sector
(Editor's note: Rankings are as of July 4, 2025.)
| Name and ticker | Market cap | Current price | Industry |
|---|---|---|---|
| Eli Lilly (NYSE:LLY) | $770 billion | $812.16 | Pharmaceuticals |
| Johnson & Johnson (NYSE:JNJ) | $405 billion | $168.30 | Pharmaceuticals |
| AbbVie (NYSE:ABBV) | $336 billion | $190.16 | Biotechnology |
| UnitedHealth Group (NYSE:UNH) | $255 billion | $280.58 | Healthcare Providers and Services |
| Abbott Laboratories (NYSE:ABT) | $220 billion | $126.56 | Healthcare Equipment and Supplies |
| Novo Nordisk (NYSE:NVO) | $241 billion | $71.68 | Pharmaceuticals |
| Novartis (NYSE:NVS) | $223 billion | $117.64 | Pharmaceuticals |
| AstraZeneca Plc (NASDAQ:AZN) | $225 billion | $72.62 | Pharmaceuticals |
| Merck (NYSE:MRK) | $213 billion | $84.85 | Pharmaceuticals |
| Intuitive Surgical (NASDAQ:ISRG) | $178 billion | $495.75 | Healthcare Equipment and Supplies |
Companies 1-3
1. Eli Lilly
- Market cap: $739.87 billion (as of July 4)
- Revenue (TTM): $49.0 billion
- Gross profit (TTM): $40.0 billion
- Five-year annualized return: 38.21%
- Year founded: 1876
Pharmaceutical giant Eli Lilly is the world's most valuable drug company. A chemist and veteran of the Union Army founded the company in 1876, and it later became the first to mass-produce insulin and the polio vaccine.
Some of its top products are diabetes medications, weight loss drugs, obesity treatments and antidepressants such as Prozac. In 2024, Eli Lilly partnered with Amazon (NASDAQ:AMZN) to offer home delivery of select medications.
2. Johnson & Johnson
- Market cap: $375.37 billion (as of July 4)
- Revenue (TTM): $89.3 billion
- Gross profit (TTM): $61.0 billion
- Five-year annualized return: 4.98%
- Year founded: 1886
Johnson & Johnson is a pharmaceutical and medical device company. Its two primary business segments are Innovative Medicine, which develops and markets prescription drugs, and MedTech, which manufactures medical devices, including Acuvue contact lenses.
Until 2023, Johnson & Johnson also had a robust consumer healthcare division that produced Tylenol, Band-Aid, and many other household names. It spun off that division into a new business, Kenvue (NYSE:KVUE).
3. AbbVie
- Market cap: $334.34 billion (as of July 4)
- Revenue (TTM): $57.4 billion
- Gross profit (TTM): $44.4 billion
- Five-year annualized return: 18.61%
- Year founded: 2012
AbbVie is a biotechnology company that develops treatments for serious diseases. It has produced therapies for illnesses, including autoimmune diseases, plaque psoriasis, blood cancers, and advanced Parkinson's disease. It also acquired Capstan Therapeutics, a cell and gene therapy company, for $2.1 billion this year.
AbbVie is a relatively new company that started as a spinoff of Abbott Laboratories (NYSE:ABT). It's now one of the better dividend stocks in the healthcare sector. It has regularly raised its dividend payout, resulting in a high dividend yield.
Companies 4-6
4. UnitedHealth Group
- Market cap: $279.90 billion (as of July 4)
- Revenue (TTM): $407.4 billion
- Gross profit (TTM): $87.5 billion
- Five-year annualized return: 2.22%
- Year founded: 1977
UnitedHealth Group (NYSE:UNH) provides health insurance and healthcare services. It sells health insurance products through its UnitedHealthcare division and offers healthcare services through its Optum division.
Although UnitedHealth Group is one of the largest healthcare companies, it has faced a number of high-profile issues. A subsidiary, Change Healthcare, was responsible for the largest reported healthcare data breach in history last year. Additionally, CEO Andrew Witty abruptly resigned in May for personal reasons.
5. Abbott Laboratories
- Market cap: $233.90 billion (as of July 4)
- Revenue (TTM): $42.3 billion
- Gross profit (TTM): $23.7 billion
- Five-year annualized return: 9.74%
- Year founded: 1888
Abbott Laboratories manufactures healthcare products and medical equipment. It has four main business segments: established pharmaceutical products, diagnostic products, nutritional products, and medical devices.
Like its spinoff AbbVie, Abbott Laboratories is popular among dividend investors. It has raised its dividend for more than 50 consecutive years, putting it on the list of Dividend Kings.
6. Novo Nordisk
- Market cap: $232.84 billion (as of July 4)
- Revenue (TTM): $47.8 billion*
- Gross profit (TTM): $40.4 billion*
- Five-year annualized return: 17.72%
- Year founded: 1923
*Converted from Danish kroner.
Based in Denmark, Novo Nordisk is a leading pharmaceutical company that develops medications for diabetes, weight loss, and rare diseases. It's the maker of Ozempic, a treatment for diabetes, and Wegovy, a weight loss drug.
Novo Nordisk has a market presence in 170 countries. It's one of the biggest companies in Europe, and at one point, its market cap surpassed Denmark's gross domestic product (GDP).
On a negative note, Novo Nordisk ousted CEO Lars Fruergaard Jorgensen in May 2025 amid increasing competition for the company's flagship anti-obesity drug. He'll remain in the role for the time being as the company looks for a successor.
Companies 7-10
7. Novartis
- Market cap: $231.32 billion (as of July 4)
- Revenue (TTM): $52.9 billion
- Gross profit (TTM): $39.9 billion
- Five-year annualized return: 12.28%
- Year founded: 1886 (Sandoz), 1970 (Ciba-Geigy), 1996 (merger of Ciba-Geigy and Sandoz)
Novartis is a Swiss pharmaceutical company. It manufactures prescription drugs for various diseases. Some of its bestselling products include Entresto, a medication used to treat heart failure; Cosentyx, a treatment for psoriasis; and Kesimpta, a treatment for certain forms of multiple sclerosis (MS).
This Swiss company is also incorporating artificial intelligence (AI) technology into its business. Novartis is partnering with Viz.ai to provide AI-powered care for cancer patients.
8. AstraZeneca
- Market cap: $215.39 billion (as of July 4)
- Revenue (TTM): $55.0 billion
- Gross profit (TTM): $44.8 billion
- Five-year annualized return: 7.68%
- Year founded: 1913 (Astra AB), Zeneca (1993), 1999 (merger of Astra AB and Zeneca)
AstraZeneca is a multinational biotech company formed through the 1999 merger of Astra, a Swiss company, and Zeneca, a British company. Its headquarters are in Cambridge, England.
This company manufactures prescription medications for many major diseases, including cardiovascular disease, metabolic disorders, renal disease, and rare diseases. It has 11 research and development (R&D) centers, 28 manufacturing sites, and a market presence in more than 130 countries.
9. Merck
- Market cap: $203.22 billion (as of July 4)
- Revenue (TTM): $63.9 billion
- Gross profit (TTM): $51.8 billion
- Five-year annualized return: 4.70%
- Year founded: 1891
Merck is a pharmaceutical company known for its impressive oncology portfolio. That includes its leading drug, Keytruda, which is also the bestselling drug worldwide. Merck also makes diabetes medications, an HPV vaccine, and a chickenpox vaccine.
This company has made several major acquisitions recently. In 2024 alone, it acquired Harpoon Therapeutics, Abceutics, EyeBio, and Modifi Biosciences. In 2025, it acquired SpringWorks Therapeutics for $3.4 billion.
10. Intuitive Surgical
- Market cap: $195.15 billion (as of July 4)
- Revenue (TTM): $8.7 billion
- Gross profit (TTM): $5.8 billion
- Five-year annualized return: 22.96%
- Year founded: 1995
Intuitive Surgical is a biotechnology company that manufactures robotic surgical systems. Its most notable product is the da Vinci system, which is used for minimally invasive surgery in more than 70 countries.
The company is currently expanding its European operations. In January 2025, it announced plans to establish a direct presence in Italy, Spain, and Portugal. Intuitive also went through a recent leadership change, promoting president Dave Rosa to CEO on July 1, 2025.
Related investing topics
Takeaways
Healthcare sector takeaways for investors
Investing in healthcare stocks can be challenging. Among the 10 largest healthcare companies, only four have outperformed the S&P 500 over the last five years.
The sector also has some unique risks. The development of new products often requires a lengthy regulatory process, particularly for pharmaceutical companies. And if a company's product may have caused harm to a consumer, there's the possibility of a lawsuit.
Like most businesses, healthcare companies have been affected by the Trump administration's import tariffs. Tariffs could increase the cost of medical devices and lead to pharmaceutical shortages.
However, there are also plenty of reasons why healthcare is an attractive sector for investors. Some of the top healthcare companies pay high dividends, which is great for those looking to build passive income. Healthcare stocks also tend to be resistant to market downturns. After all, no matter how the economy is doing, people always need healthcare.
